EMA Safety Panel Recommends Withdrawing Esmya Authorizations
Executive Summary
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the European Medicines Agency’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
You may also be interested in...
Gedeon Richter Gearing Up For Denosumab And Tocilizumab
Hungary’s Gedeon Richter is continuing efforts to bring multiple biosimilars to market, while reaping the benefits of the biosimilar to Eli Lilly’s Forsteo (teriparatide) in the EU and Japan. Management discussed Richter’s achievements on the company’s first-half earnings call, while also commenting on how markets have reacted to the COVID-19 pandemic.
Ulipristal Suspended In EU Pending Further Review
Gedeon Richter's Esmya should not be prescribed to women while the European Medicines Agency again reviews the risk of serious hepatic injury.
Alvogen Targets Esmya With First European Rival
Alvogen has gained European approvals for a rival to Gedeon Richter’s Esmya through the decentralized procedure.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: